You are here:Home-Research Areas-Infection-HCV Infection

Request The Product List ofHCV Infection HCV Infection

Cat. No. Product Name CAS No. Information
PC-63383

GSK-2878175

1423007-82-2

GSK-2878175 (GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B polymerase inhibitor with EC50 of 0.4-9.7 nM; exhibited low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons, displayed a 60-63 h half-life and a robust decrease in viral RNA levels in HCV infected patients relative to GSK5852.

HCV Infection

Phase 2 Clinical

PC-62103

ITX-5061 hydrochloride

1252679-52-9

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels; inhibits SR-BI-dependent uptake of HDL-CE in transfected cells, decreases the fractional catabolic rate of HDL-CE and reduced its hepatic uptake in mice; inhibits HCVcc and HCVpp infection of primary human hepatocytes and/or human hepatoma cell lines and has minimal effects on HCV RNA replication.

HCV Infection

Phase 2 Clinical

PC-62102

ITX-5061

848144-15-0

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels; inhibits SR-BI-dependent uptake of HDL-CE in transfected cells, decreases the fractional catabolic rate of HDL-CE and reduced its hepatic uptake in mice; inhibits HCVcc and HCVpp infection of primary human hepatocytes and/or human hepatoma cell lines and has minimal effects on HCV RNA replication.

HCV Infection

Phase 2 Clinical

PC-61440

Voxilaprevir

1535212-07-7

Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.

HCV Infection

Phase 2 Clinical

PC-60952

Deleobuvir

863884-77-9

Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients.

HCV Infection

Phase 3 Clinical

PC-60428

GSK-2485852

1331942-30-3

GSK-2485852 (GSK2485852, GSK5852) is a highly potent, selective HCV NS5B polymerase inhibitor with IC50 of 3.0 and 1.6 nM for HCV genotypes 1a and 1b in replicon assay, respectively; displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations P495L, M423T, C316Y, and Y448H; targets NNI palm site 2 of NS5B and inhibits all HCV genotypes.

HCV Infection

Phase 1 Clinical

PC-35444

Coblopasvir

1312608-46-0 Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.

HCV Infection

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com